Clinical associations of the metabolic syndrome in systemic lupus erythematosus: Data from an international inception cohort

Annals of the Rheumatic Diseases

Volumn 72, Issue 8, 2013, Pages 1308-1314

  Parker, Ben ^a   Urowitz, Murray B ^b   Gladman, Dafna D ^b   Lunt, Mark ^a,c   Bae, Sang Cheol ^d   Sanchez Guerrero, Jorge ^e   Romero Diaz, Juanita ^e   Gordon, Caroline ^f   Wallace, Daniel J ^g   Clarke, Ann E ^h   Bernatsky, Sasha ^h   Ginzler, Ellen M ⁱ   Isenberg, David A ^j   Rahman, Anisur ^j   Merrill, Joan T ^k   Alarcón, Graciela S ^l   Fessler, Barri J ^l   Fortin, Paul R ^m   Hanly, John G ⁿ   Petri, Michelle ^o   Steinsson, Kristjan ^p   Dooley, Mary Anne ^q   Manzi, Susan ^r   Khamashta, Munther A ^s   Ramsey Goldman, Rosalind ^t   Zoma, Asad A ^u   Sturfelt, Gunnar K ^v   Nived, Ola ^v   Aranow, Cynthia ^w   MacKay, Meggan ^w   Ramos Casals, Manuel ^x   Van Vollenhoven, Raymond F ^y   Kalunian, Kenneth C ^z   Ruiz Irastorza, Guillermo ^aa   Lim, Sam ^ab   Kamen, Diane L ^ac   Peschken, Christine A ^ad   Inanc, Murat ^ae   Bruce, Ian N ^a,c   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d Hanyang University Hospital for Rheumatic Diseases   (South Korea)

^e INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h MONTREAL GENERAL HOSPITAL   (Canada)

ⁱ Downstate Health Sciences University   (United States)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^l University of Alabama at Birmingham   (United States)

^m LAVAL UNIVERSITY   (Canada)

ⁿ QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^o JOHNS HOPKINS UNIVERSITY   (United States)

^p LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^q UNIVERSITY OF NORTH CAROLINA   (United States)

^r University of North Carolina ^*  (United States)

^s ST THOMAS HOSPITAL   (United Kingdom)

^t NORTHWESTERN UNIVERSITY   (United States)

^u HAIRMYRES HOSPITAL   (United Kingdom)

^v LUND UNIVERSITY HOSPITAL   (Sweden)

^w FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^x HOSPITAL CLÍNIC   (Spain)

^y KAROLINSKA INSTITUTE   (Sweden)

^z UNIVERSITY OF CALIFORNIA   (United States)

^aa HOSPITAL DE CRUCES   (Spain)

^ab EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ac MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^ad UNIVERSITY OF MANITOBA   (Canada)

^ae ISTANBUL UNIVERSITY   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE PREDISPOSITION; DRUG DOSE COMPARISON; ETHNICITY; FEMALE; HISPANIC; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KIDNEY DISEASE; KOREAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

CARDIOVASCULAR DISEASE; EPIDEMIOLOGY; INFLAMMATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ASIA; COHORT STUDIES; COMORBIDITY; EUROPE; FEMALE; HUMANS; INTERNATIONAL COOPERATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METABOLIC SYNDROME X; NORTH AMERICA; PREVALENCE; REGISTRIES;

EID: 84880214160     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202106     Document Type: Article

References (34)

1. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15. (Pubitemid 27084212)
2. Petri MA, Kiani AN, Post W, et al. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011;70:760-5.
3. Ahmad Y, Shelmerdine J, Bodill H, et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology 2007;46:983-8. (Pubitemid 47062508)
4. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406. (Pubitemid 37542988)
5. El-Magadmi M, Bodill H, Ahmad Y, et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004;110:399-404. (Pubitemid 38993848)
6. Bruce IN, Urowitz MB, Gladman DD, et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003;48:3159-67. (Pubitemid 37409327)
7. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7. (Pubitemid 32977500)
8. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-80.
9. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev 2008;29:777-822.
10. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and international association for the Study of Obesity. Circulation 2009;120: 1640-5.
11. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007;49:403-14. (Pubitemid 46135879)
12. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-304. (Pubitemid 41242486)
13. Wannamethee SG, Shaper AG, Lennon L, et al. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005;165:2644-50. (Pubitemid 41785063)
14. Grundy SM. Does the metabolic syndrome exist? Diabetes Care 2006;29:1689-92. (Pubitemid 44127605)
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001; 285: 2486-97.
16. Parker B, Bruce IN. The metabolic syndrome in systemic lupus erythematosus. Rheum Dis Clin North Am 2010;36:81-97.
17. Parker B, Ahmad Y, Shelmerdine J, et al. An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. Lupus 2011;20:1459-65.
18. Sabio JM, Zamora-Pasadas M, Jimenez-Jaimez J, et al. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus 2008;17:849-59.
19. Chung CP, Avalos I, Oeser A, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007;66:208-14. (Pubitemid 46226056)
20. El-Magadmi M, Ahmad Y, Turkie W, et al. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 2006;33:50-6. (Pubitemid 43054279)
21. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
22. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91. (Pubitemid 34118775)
23. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9. (Pubitemid 26085211)
24. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999;138: S419-20. (Pubitemid 29523224)
25. Tso TK , Huang WN, Huang HY, et al. Elevation of plasma interleukin-18 concentration is associated with insulin levels in patients with systemic lupus erythematosus. Lupus 2006; 15: 207-12.
26. Petri M, Spence D, Bone LR, et al. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine 1992;71:291-302.
27. Posadas-Romero C, Torres-Tamayo M, Zamora-Gonzalez J, et al. High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus. Arthritis Rheum 2004;50:160-5. (Pubitemid 38084300)
28. Rojas R, guilar-Salinas CA, Jimenez-Corona A, et al. Metabolic syndrome in Mexican adults: results from the National Health and Nutrition Survey 2006. Salud Publica Mex 2010;52(Suppl. 1):S11-18.
29. Lorenzo C, Williams K, Hunt KJ, et al. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007;30:8-13. (Pubitemid 46052493)
30. Park HS, Park CY, Oh SW, et al. Prevalence of obesity and metabolic syndrome in Korean adults. Obes Rev 2008;9:104-7. (Pubitemid 351197438)
31. Bellomio V, Spindler A, Lucero E, et al. Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus 2009;18:1019-25.
32. Claes K, Meier-Kriesche HU, Schold JD, et al. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol Dial Transplant 2012;27:850-7.
33. van Leuven SI, van Wijk DF, Volger OL, et al. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis 2010;211:231-6.
34. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7. (Pubitemid 34304256)